Zepbound vs Foundayo (Orforglipron): Pill vs Shot

For the first time, the choice between two FDA-approved obesity drugs from the same company comes down to a pill versus a shot. Zepbound is injectable tirzepatide — the most powerful weight-loss drug on the market, given as a once-weekly subcutaneous injection. Foundayo is orforglipron — Eli Lilly's newly FDA-approved once-daily oral GLP-1, the first true non-peptide GLP-1 tablet¹⁸. They are both from Lilly, both FDA-approved for chronic weight management, and they pull people in opposite directions: one is the stronger drug, the other is the more convenient one. This page is the honest head-to-head — what each actually delivers, where the trade-off really lands, and how to think about price.

If you want the standalone explainer on the pill itself, we cover it in full in our orforglipron (Foundayo) explainer. This page is the decision between the two.

The single sentence that frames everything below: Zepbound produces more weight loss; Foundayo is easier to take. Almost every difference is a consequence of that trade-off.

The mechanism difference drives the efficacy gap

Zepbound (tirzepatide) is a dual agonist — it activates two gut-hormone receptors, GLP-1 and GIP. Foundayo (orforglipron) is a GLP-1 receptor agonist only. More receptors is part of why tirzepatide is the strongest agent in the class, and it is the reason Foundayo's appetite effect looks closer to injectable semaglutide's than to Zepbound's⁴.

The other structural difference is what makes one a pill and one a shot. Tirzepatide is a peptide — a protein-like chain the gut would destroy if swallowed, which is why it must be injected. Orforglipron is a small molecule — chemically rugged enough to survive digestion, so it can be a real once-daily tablet taken with or without food, with no empty-stomach ritual⁸. (That is also why there is no oral tirzepatide pill: the peptide chemistry that lets orforglipron work by mouth does not transfer to tirzepatide.)

Efficacy: the numbers favor Zepbound

This is where the honest version matters, because the headline trial figures for the two drugs are easy to misread.

Zepbound (tirzepatide). In its pivotal SURMOUNT-1 obesity trial — a 72-week, placebo-controlled study in adults with obesity — tirzepatide produced roughly 15% mean weight loss at 5 mg, ~19.5% at 10 mg, and ~21% at the 15-mg dose, versus about 3% on placebo¹. That ~21% figure at the top dose is the high-water mark for any approved obesity drug, and it comes from the actual marketed dose.

Foundayo (orforglipron). In its pivotal ATTAIN-1 obesity trial — also 72 weeks, in 3,127 adults with obesity without diabetes — mean weight change was −7.5% at 6 mg, −8.4% at 12 mg, and −11.2% at the 36-mg dose, versus −2.1% on placebo². In ATTAIN-2, which enrolled people who had obesity and type 2 diabetes, weight loss was more modest, as it typically is in that population³.

Here is the catch that the splashy "orforglipron weight loss" headlines skip: that ~11% number came from the experimental 36-mg dose, but the approved Foundayo label tops out at 5.5 mg (titrated 0.8 mg → 2.5 mg → 5.5 mg, each step at least 30 days apart)⁸. So the real-world weight loss at the marketed dose will not necessarily match the headline trial figure from a higher dose that is not on the label. The honest comparison is therefore even more lopsided than "21% vs 11%" — Zepbound's number is from its real top dose, while Foundayo's best trial number is from a dose you cannot actually be prescribed.

For context, orforglipron's effect lands close to injectable semaglutide's range: Wegovy's STEP-1 trial reached about 15% mean weight loss at 68 weeks⁴. On the diabetes side, tirzepatide beat injectable semaglutide head-to-head in SURPASS-2⁵ — there is no equivalent head-to-head win for orforglipron. And crucially, no trial has directly compared Zepbound and Foundayo. Every number above comes from separate trials with different populations and designs, so the cross-comparison is strongly suggestive, not a head-to-head result.

Convenience: the case for Foundayo

If efficacy is Zepbound's column, convenience is Foundayo's — and for many people it is decisive.

Foundayo is a once-daily tablet swallowed whole, with or without food, no water-timing or empty-stomach rules⁸. There are no needles, no injection technique to learn, no pens to refrigerate, and nothing to dispose of as sharps. For people with a genuine needle phobia, or who simply will not stick to a weekly injection, a real oral GLP-1 is a meaningful change in access — even if the average weight loss is smaller.

Zepbound, by contrast, is a once-weekly subcutaneous injection. Many people find a weekly shot easier to remember than a daily pill, and the single-use pen is straightforward — but it is still an injection, with storage requirements and the learning curve we cover in how to inject Zepbound. The trade is real in both directions: weekly-but-injected versus daily-but-oral.

Side effects and the thyroid warning are largely shared

Both drugs are GLP-1-based, so they share the same gut-driven side-effect profile: nausea, constipation, diarrhea, vomiting, dyspepsia, and abdominal pain are the most common reactions for each, usually worst during dose escalation and easing over time⁸. Foundayo's label additionally lists headache, fatigue, belching, reflux, flatulence, and hair loss among reactions occurring in ≥5% of patients⁸; Zepbound's GI profile is detailed in our Zepbound side effects guide.

Both also carry the same boxed warning for thyroid C-cell tumors — a class warning based on rodent data, with both drugs contraindicated in people who have a personal or family history of medullary thyroid carcinoma or MEN 2⁸. Being a pill does not soften the underlying pharmacology; we explain the warning in the tirzepatide thyroid cancer warning. On safety, then, the two are far more alike than different — the real divergence is efficacy and route, not risk class.

One shared caveat worth naming: with either drug, weight tends to come back when you stop. Tirzepatide's SURMOUNT-4 trial showed that people who switched to placebo after the initial reduction regained a substantial share of the lost weight, while those who continued kept losing⁶. These are maintenance medications, not short courses — a point that applies equally to the pill and the shot. We unpack it in what happens when you stop tirzepatide.

Price: what to expect in 2026

Pricing is the one area that shifts fastest, so treat this as current-2026 framing rather than a fixed quote. As of 2026, both are brand-name Lilly drugs without generics, so list prices for each run into the high hundreds to roughly a thousand dollars a month before insurance or manufacturer savings. Coverage for obesity remains inconsistent across plans, which is why so many people pay cash or hunt for savings programs — the same dynamic we map for the injectable in Zepbound cost and savings and does insurance cover Zepbound.

The honest expectation: do not assume the pill is automatically the cheaper option just because it is a tablet. Lilly has signaled that an oral GLP-1 is meant to widen access, and self-pay vial channels have pushed injectable tirzepatide's cash price down, so the two may land closer than people expect. Because exact prices, savings-card terms, and coverage change month to month, confirm the current cash price, any manufacturer savings program, and your plan's formulary status for both drugs before deciding — the cheaper choice in 2026 depends on your specific coverage, not on pill-versus-shot alone.

So which should you choose?

There is no universal winner — there is a trade-off, and which side wins depends on what you are optimizing for.

Choose Zepbound if maximum weight loss is the goal. It is the stronger drug, with ~21% mean loss at its top dose from a real marketed dose, and the deepest trial record in the class¹. The cost is a weekly injection.

Choose Foundayo if avoiding needles is the deciding factor. It is a genuine, FDA-approved once-daily GLP-1 pill with no injection and no food rules — at the price of a smaller average weight loss, closer to semaglutide's range than to Zepbound's²⁴. For people who will not inject, a pill they will actually take beats a stronger drug they won't.

Either way, this is a medical decision: candidacy, dose titration, the GI and thyroid cautions, and the maintenance-not-a-cure reality all need a clinician. To weigh the full landscape, start with our tirzepatide evidence guide, compare the two approved injectable mechanisms in tirzepatide vs semaglutide, look at the next investigational tier in retatrutide vs tirzepatide, and see how prescribers stack up in our best tirzepatide providers overview.

The bottom line

Zepbound (injectable tirzepatide) and Foundayo (oral orforglipron) are both FDA-approved Lilly obesity drugs that ask you to pick a side of one trade-off. Zepbound is the dual GIP/GLP-1 injectable with the strongest weight-loss data in the class — about 21% at its top dose over 72 weeks, from a real marketed dose¹. Foundayo is the first true oral non-peptide GLP-1, a once-daily pill with no needles and no food rules, whose best trial figure (~11%) came from a 36-mg experimental dose above its 5.5-mg label ceiling — so its real-world effect is more modest and closer to semaglutide's range²⁴⁸. They share a GI side-effect profile and the class thyroid boxed warning, and no trial has compared them head-to-head. The fair verdict: Zepbound is the more powerful drug; Foundayo is the more convenient one. Which is right for you is a conversation to have with a clinician, not a question pill-versus-shot answers on its own.